Abstract
BackgroundDespite significant progress in cancer immunotherapy in recent years, resistance to existing immune checkpoint therapies (ICT) is common. V-domain Ig suppressor of T cell activation (VISTA), a predominantly myeloid immune...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have